Is CAR-T Really Putting Us on Road to Gene Therapy?
January 3, 2018
(Managed Care Magazine) – For decades, researchers, some physicians, and a few patients have had visions of treatments that would go in and fix diseases at the genetic level. Last year, those dreams took on some reality as Kymriah and Yescarta became the first FDA-approved gene therapy treatments. But there’s a catch: Are they really gene therapy? For a long time, gene therapy has been viewed as therapy that would fix or replace a specific aberrant gene causing an inherited condition or sparking a disease. By that definition, Kymriah and Yescarta are not, strictly speaking, gene therapy.